TEL AVIV, Israel, March 17, 2016 -- Elbit Imaging Ltd. ("Company") (TASE:EMITF) (NASDAQ:EMITF) announced today that it has received a written proposal from the independent committee of its subsidiary, Elbit Medical Technologies Ltd. to convert all the outstanding debts of Elbit Medical to the Company, which as of today amount to approximately NIS 146 million ($37.9 million) into Elbit Medical's shares (the "Proposal").
The Proposal and its terms, shall be considered by the Company's authorized organs (including its independent committee) in accordance with the applicable law. The Company will publish an immediate report of its decisions with respect to the Proposal, as required by the applicable law.
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotels - hotels operation and management. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects.
Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2014, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
For Further Information: Company Contact Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]


Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 



